利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.039 秒)

    Methods of treating cancer with HDAC inhibitors
    2.
    发明授权
    Methods of treating cancer with HDAC inhibitors 有权
    用HDAC抑制剂治疗癌症的方法

    公开(公告)号：US07399787B2

    公开(公告)日：2008-07-15

    申请号：US10616649

    申请日：2003-07-09

    申请人： Judy H. Chiao ,  Nicholas G. Bacopoulos ,  Thomas A. Miller ,  Carolyn M. Paradise ,  Victoria M. Richon

    发明人： Judy H. Chiao ,  Nicholas G. Bacopoulos ,  Thomas A. Miller ,  Carolyn M. Paradise ,  Victoria M. Richon

    IPC分类号： A61K31/19

    CPC分类号： A61K9/4866 ,  A61K9/0019 ,  A61K9/1652 ,  A61K31/13 ,  A61K31/164 ,  A61K31/165 ,  A61K31/19 ,  A61K31/44 ,  A61K38/12 ,  A61K47/12 ,  A61K47/38

    摘要： The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

    摘要翻译： 本发明提供了通过施用包含有效的HDAC抑制剂的药物组合物来治疗癌症，化学预防，选择性诱导肿瘤细胞的终末分化，细胞生长停滞和/或细胞凋亡和/或抑制组蛋白脱乙酰酶（HDAC）的方法。 本发明的药物组合物中活性化合物的口服生物利用度令人惊奇的高。 此外，药物组合物在长时间内意外地引起活性化合物的高，治疗有效的血液水平。 本发明进一步提供这些药物组合物的安全的每日给药方案，其易于遵循，并且其在体内导致治疗有效量的HDAC抑制剂。

    Methods of treating cancer with HDAC inhibitors
    6.
    发明申请
    Methods of treating cancer with HDAC inhibitors 审中-公开
    用HDAC抑制剂治疗癌症的方法

    公开(公告)号：US20090012175A1

    公开(公告)日：2009-01-08

    申请号：US12217843

    申请日：2008-07-08

    申请人： Nicholas G. Bacopoulos ,  Judy H. Chiao ,  Thomas A. Miller ,  Carolyn M. Paradise ,  Victoria M. Richon

    发明人： Nicholas G. Bacopoulos ,  Judy H. Chiao ,  Thomas A. Miller ,  Carolyn M. Paradise ,  Victoria M. Richon

    IPC分类号： A61K31/192 ,  A61P35/00

    CPC分类号： A61K31/16 ,  A61K31/185

    摘要： The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

    摘要翻译： 本发明提供了通过施用包含有效的HDAC抑制剂的药物组合物来治疗癌症，化学预防，选择性诱导肿瘤细胞的终末分化，细胞生长停滞和/或细胞凋亡和/或抑制组蛋白脱乙酰酶（HDAC）的方法。 本发明的药物组合物中活性化合物的口服生物利用度令人惊奇的高。 此外，药物组合物在长时间内意外地引起活性化合物的高，治疗有效的血液水平。 本发明进一步提供这些药物组合物的安全的每日给药方案，其易于遵循，并且其在体内导致治疗有效量的HDAC抑制剂。

    Methods of treating cancer with HDAC inhibitors
    7.
    发明申请
    Methods of treating cancer with HDAC inhibitors 审中-公开
    用HDAC抑制剂治疗癌症的方法

    公开(公告)号：US20080227862A1

    公开(公告)日：2008-09-18

    申请号：US11980994

    申请日：2007-10-30

    申请人： Victoria M. Richon ,  Judy H. Chiao ,  Thomas A. Miller ,  Nicholas G. Bacopoulos ,  Carolyn M. Paradise

    发明人： Victoria M. Richon ,  Judy H. Chiao ,  Thomas A. Miller ,  Nicholas G. Bacopoulos ,  Carolyn M. Paradise

    IPC分类号： A61K31/167 ,  A61P19/00

    CPC分类号： A61K31/19 ,  A61K31/44 ,  A61K38/12

    摘要： The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

    摘要翻译： 本发明涉及治疗癌症例如白血病的方法。 更具体地说，本发明涉及治疗急性和慢性白血病的方法，包括急性淋巴细胞白血病（ALL），急性骨髓性白血病（AML），慢性淋巴细胞白血病（CLL），慢性骨髓性白血病（CML）和毛细胞白血病 包含HDAC抑制剂的药物组合物，例如辛二酰苯胺异羟肟酸（SAHA）。 药物组合物的口服制剂具有有利的药代动力学特征，例如高生物利用度，并且令人惊讶地在长时间内引起活性化合物的高血药浓度。 本发明进一步提供这些药物组合物的安全的每日给药方案，其易于遵循，并且其在体内导致治疗有效量的HDAC抑制剂。

    Method of treating chemical dependencies using sertraline
    8.
    发明授权
    Method of treating chemical dependencies using sertraline 失效
    使用舍曲林治疗化学依赖性的方法

    公开(公告)号：US5130338A

    公开(公告)日：1992-07-14

    申请号：US663073

    申请日：1991-02-28

    申请人： Nicholas G. Bacopoulos ,  Peter A. Blick ,  B. Kenneth Koe ,  Evan R. Norris

    发明人： Nicholas G. Bacopoulos ,  Peter A. Blick ,  B. Kenneth Koe ,  Evan R. Norris

    IPC分类号： A61K31/135

    CPC分类号： A61K31/135 ,  Y10S514/811

    摘要： A method of treating a chemical dependency in a mammal, comprising administering to a mammal in need of such treatment an amount of the compound (1S-cis)-4-(3, 4-dichlorophenyl)-1,2,3,4-tetraahydro-N-methyl-1-naphthalenamine, also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in reducing or alleviating such dependency.

    摘要翻译： 一种治疗哺乳动物的化学依赖性的方法，包括向需要这种治疗的哺乳动物施用一定量的化合物（1S-顺式）-4-（3,4-二氯苯基）-1,2,3,4-四氢 - 四氢-N-甲基-1-萘胺，也称为舍曲林的通用名称，或其药学上可接受的盐，有效降低或减轻这种依赖性。